Homepage > Company > Media > Pharma News > 2022 > Clovis Abandons Previous FDA Approval of Rubraca Following Study Data

Clovis Abandons Previous FDA Approval of Rubraca Following Study Data

Clovis Oncology has requested a withdrawal of FDA approval of Rubraca (rucaparib) for treating patients with BRCA-mutated ovarian cancer after two or more chemotherapies.

The withdrawal was based on disappointing data from a study that enrolled 564 patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who were in response to platinum-based chemotherapy.

The results were not statistically significant in participants taking Rubraca compared with those who were given a placebo.

The company has also requested a withdrawal of the indication in Europe.

June 22, 2022

https://www.fdanews.com/

Read also

Eli Lilly's weight loss drug could help sleep apnea patients

Shares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial of GLP-1 its weight loss drug Zepb...

Essential Pharma acquires Reminyl from Janssen Pharmaceutica

Speciality pharmaceutical group Essential Pharma has concluded the acquisition of Reminyl (Galantamine) oral capsules from Johnson & Johnson company Janssen Pharmaceutica.

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

GSK plc GSK announced that the FDA has accepted its biologics license application (BLA) seeking approval of its 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY. The FDA has granted a st...

American Brain Foundation funds research in Lewy body dementia, neuroinflammation

DENVER — The American Brain Foundation is funding research to find a cure for Lewy body dementia and discover breakthroughs in neuroinflammation, the group’s executive director said at the America...